Clinical Trials Search Results
Quick Links
Dictionary
Funding Opportunities
NCI Publications
NCI Calendar
Español
NCI Highlights
Chemo Extends Life in Advanced Prostate Cancer
Temozolomide Plus Radiation Helps Brain Cancer
Confirmed: Raloxifene Drops Risk of Breast Cancer
Bortezomib Delays Progression of Multiple Myeloma
Annual Report to the Nation
Past Highlights
Results:
11-20 of 229
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
6/8/2004
First Published:
6/23/2003
11.
Phase III Randomized Study of Paclitaxel and Cisplatin Versus Vinorelbine and Cisplatin Versus Gemcitabine and Cisplatin Versus Topotecan and Cisplatin in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
GOG-0204
Last Modified:
11/14/2003
First Published:
10/25/2003
12.
Phase III Randomized Study of Dacarbazine and/or Cisplatin Versus Complete Metastasectomy in Patients With Stage IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
16 and over
NCI
NCI-03-C-0279
Last Modified:
10/4/2004
First Published:
9/25/2004
13.
Phase III Randomized Study of Three Different Adjuvant Chemotherapy Regimens Comprising Docetaxel, Doxorubicin, and Cyclophosphamide Versus Dose-Dense Doxorubicin, Cyclophosphamide, and Paclitaxel Versus Dose-Dense Doxorubicin, Cyclophosphamide, Paclitaxel, and Gemcitabine in Women With Node-Positive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Not specified
NCI
NSABP-B-38
Last Modified:
5/3/2004
First Published:
3/24/2003
14.
Phase I/II Study of Bortezomib Alone or With Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI
NCI-03-C-0096
NCI-5748
Last Modified:
12/31/2003
First Published:
8/24/2003
15.
Phase I/II Study of Anidulafungin in Immunocompromised Children With Neutropenia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Supportive care
Active
2 to 17
NCI
NCI-03-C-0229C
Last Modified:
4/29/2004
First Published:
12/23/2003
16.
Phase I/II Study of Vaccination Comprising a-1,3-Galactosyltransferase-Expressing Allogeneic Tumor Cells (HyperAcute™ Lung Cancer Vaccine) in Patients With Advanced Refractory or Recurrent Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
NCI-04-C-0049
NLGC-0101
Last Modified:
7/20/2004
First Published:
2/20/2004
17.
Phase I/II Study of Tipifarnib and Radiotherapy in Pediatric Patients With Non-Disseminated Intrinsic Diffuse Brainstem Gliomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
3 to 21
NCI
PBTC-014
Last Modified:
7/7/2004
First Published:
5/28/2004
18.
Phase I/II Study of FR901228 in Patients With Progressive High-Grade Gliomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI
NABTC-0303
Last Modified:
9/16/2004
First Published:
5/23/2003
19.
Phase I/II Study of Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI
NCI-03-C-0162
NCI-5855
Last Modified:
7/9/2004
First Published:
5/23/2003
20.
Phase I/II Randomized Pilot Study of Sequential Vaccination With Fowlpox-PSA-TRICOM Vaccine With or Without Vaccinia-PSA-TRICOM Vaccine, Sargramostim (GM-CSF), and Fowlpox-GM-CSF in Patients With Metastatic Prostate Cancer (Phase I closed to accrual as of 6/2/04.)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI
NCI-03-C-0176
NCI-5911
Select All on One Page
< Previous
1
2
3
4
5
Next >
Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Site Help
|
Site Map
A Service of the National Cancer Institute
